PhaseBio Pharmaceuticals Book value per Share

Book value per Share of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book value per Share growth rates and interactive chart. Book value per common share (or, simply book value per share - BVPS) is a method to calculate the per-share value of a company based on common shareholders' equity in the company. Should the company dissolve, the book value per common share indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid. It is calculated as Total Shareholder's Equity minus Preferred Equity and divided by the number of shares outstanding.


Highlights and Quick Summary

  • Book value per Share for the quarter ending September 29, 2021 was -1.05 (a 162.14% increase compared to previous quarter)
  • Year-over-year quarterly Book value per Share increased by 22.19%
  • Annual Book value per Share for 2020 was -0.87 (a -139.76% decrease from previous year)
  • Annual Book value per Share for 2019 was 2.18 (a -77.28% decrease from previous year)
  • Annual Book value per Share for 2018 was 9.6 (a -3206.67% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book value per Share of PhaseBio Pharmaceuticals

Most recent Book value per Shareof PHAS including historical data for past 10 years.

Interactive Chart of Book value per Share of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Book value per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -1.05 -0.4 0.27
2020 -0.86 0.15 0.92 1.86 -0.87
2019 2.18 2.47 2.92 1.8 2.18
2018 9.6 12.48 0.0 0.0 9.6
2017 0.0 -0.31
2016 0.09

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.